Skint9 Activators
Chemical activators of Skint9 operate through a cascade of intracellular signaling that culminates in the phosphorylation and activation of this protein. Forskolin directly targets adenylyl cyclase, the enzyme responsible for converting ATP to cyclic AMP (cAMP). The rise in cAMP levels triggers protein kinase A (PKA), which then phosphorylates Skint9. Similarly, Isoproterenol and Salbutamol, as beta-adrenergic agonists, bind to their respective receptors to increase cAMP levels, thereby providing another route for PKA activation and subsequent Skint9 phosphorylation. Epinephrine also engages with adrenergic receptors to elevate cAMP and activate PKA, which can act on Skint9.
In addition to these, other compounds like IBMX and Rolipram extend the influence on Skint9 by inhibiting phosphodiesterases, the enzymes that degrade cAMP. This inhibition leads to sustained cAMP levels, with IBMX having a broader effect on various phosphodiesterases and Rolipram specifically inhibiting phosphodiesterase 4 (PDE4). The resulting augmentation in PKA activity facilitates Skint9 phosphorylation. Prostaglandin E2 and PGE1 both exert their actions through G protein-coupled receptors that increase cAMP levels, activating PKA and influencing Skint9 activity. Dopamine, upon interacting with D1-like receptors, and Histamine, through H2 receptor activation, follow a similar paradigm by boosting cAMP and mobilizing PKA to activate Skint9. Anagrelide's inhibition of PDE3 also causes an upswing in cAMP levels, enhancing PKA-mediated phosphorylation of Skint9. Lastly, Terbutaline acts through the beta2-adrenergic pathway to raise cAMP and activate PKA, paving the way for Skint9 activation. Each of these chemicals, through their unique interactions with cellular mechanisms, ultimately converge on the pathway leading to Skint9 activation via phosphorylation by PKA.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, binds to beta-adrenoceptors, stimulating adenylyl cyclase and increasing intracellular cAMP. The rise in cAMP levels activates PKA, which in turn can phosphorylate and activate Skint9. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine interacts with adrenergic receptors, particularly beta receptors, which leads to increased cAMP and activation of PKA. PKA then phosphorylates target proteins, potentially including Skint9, thereby activating it. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, by acting as a beta2-adrenergic agonist, increases intracellular cAMP levels, which in turn leads to the activation of PKA. PKA can phosphorylate and activate Skint9 in cells where this pathway is relevant. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterases that break down cAMP, resulting in sustained cAMP levels and PKA activation. PKA can then phosphorylate and activate Skint9 through downstream signaling events. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to increased cAMP levels within the cell, which then activates PKA. Activated PKA may phosphorylate and activate Skint9 as part of its downstream effectors. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 binds to its G protein-coupled receptors, leading to increased cAMP production and PKA activation. PKA, as a kinase, can phosphorylate and activate Skint9. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine, when interacting with D1-like receptors, causes an increase in cAMP, leading to PKA activation. The activated PKA can phosphorylate and functionally activate Skint9. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, through H2 receptor activation, increases cAMP levels within the cell, leading to PKA activation. PKA can then phosphorylate and activate Skint9 as part of its downstream signaling targets. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, leading to increased cAMP levels and subsequent PKA activation. PKA can phosphorylate and activate Skint9 as a consequence of heightened cAMP levels. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline, as a beta2-adrenergic agonist, elevates intracellular cAMP levels, leading to PKA activation. PKA can then phosphorylate and activate Skint9 as part of the cellular response to this agonist. | ||||||